Role of gamma probes in performing minimally invasive parathyroidectomy in patients with primary hyperparathyroidism: optimization of preoperative and intraoperative procedures

Domenico Rubello, Andrea Piotto, Dario Casara, Pier Carlo Muzzio, Brahm Shapiro and Maria Rosa Pelizzo

Nuclear Medicine Service, Department of Radiotherapy, Regional Hospital of Padua, Padua, Italy, Department of Clinical Surgery and Oncological Radiology Service, University of Padua, Padua, Italy and Nuclear Medicine Service, Department of Radiology, Michigan University Medical Center, Ann Arbor, Michigan, USA

(Correspondence should be addressed to D Rubello, Servizio di Medicina Nucleare 2, Dipartimento di Radiotherapia, Azienda Ospedaliera di Padova via Giustiniani 2, 35100, Padua, Italy; Email: domenico.rubello@sanita.padova.it)

Abstract

Objective: In the last decade, surgery of primary hyperparathyroidism (HPT) due to a solitary adenoma has moved on from the traditional wide bilateral neck exploration (BNE) to more limited approaches such as unilateral neck exploration and minimally invasive parathyroidectomy.

Design: To define the role of intraoperative gamma probe and injection of a low 99mTc-MIBI dose in performing minimally invasive radio-guided surgery (MIRS) in HPT patients with a solitary parathyroid adenoma.

Methods: From September 1999 to July 2002, 214 patients with primary HPT entered the study. All patients were preoperatively investigated by a 99mTc-pertechnetate/MIBI subtraction scan and high-resolution neck ultrasound. The intraoperative technique we developed differs from other previously described techniques being based on the injection of a low (37 MBq) MIBI dose in the operating theatre a few minutes before the beginning of intervention.

Results: On the basis of scan/ultrasound findings 147 patients were selected for a MIRS and 144 of them (98%) were successfully treated by this approach: a solitary parathyroid adenoma was removed through a small 2–2.5 cm skin incision with a mean operative time of 35 min, and a mean hospital stay of 1.2 days. In the other 67 patients with scan/ultrasound evidence of concomitant nodular goiter (n = 45) or multi-gland disease (n = 13) or with a negative scan (n = 9), the gamma probe was utilized during a traditional BNE. A low 37 MBq MIBI dose proved to be sufficient to perform a MIRS; moreover it delivered to the patient and surgeon a low, negligible, radiation exposure dose.

Conclusions: The combination of a 99mTc-pertechnetate/MIBI subtraction scan and neck ultrasound appears to be an accurate imaging protocol in selecting primary HPT patients as candidates for a MIRS. A MIBI dose as low as 37 MBq injected in the operating theatre just before the start of surgery appears to be adequate to perform radio-guided surgery.

Introduction

The traditional approach to patients with primary hyperparathyroidism (HPT) consists of bilateral neck exploration (BNE) with the aim of visualizing all parathyroid glands and removing the enlarged ones (1). Several surgical protocols also include biopsy of the normal-sized glands in order to discover possible glandular hyperplasia (2). BNE has been shown to have a success rate as high as 95% in the hands of experienced surgeons (1). In surgical centers where BNE is routinely performed poor clinical value is usually assigned to preoperative localizing imaging, which is preferably reserved for patients with persistent/recurrent HPT before re-operation (3). It appears difficult to propose an alternative surgical approach able to further improve the efficacy of BNE. However, some considerations can be made: (i) without preoperative imaging, the parathyroid glands localized in orthotopic sites are easily detected intraoperatively – conversely, the ectopic glands can be missed; (ii) some morbidity (hypoparathyroidism and laryngeal nerve injury) is associated with BNE, especially when biopsy of normal-sized glands is applied or when re-operation is required for persistent/recurrent HPT (2, 4); and (iii) cosmetic results are less than optimal. Furthermore,
since primary HPT is caused by a solitary adenoma in about 85% of cases, BNE is felt by many surgeons to be overtreatment in the majority of these patients. For these reasons, parathyroid surgery has progressively moved towards some type of limited neck exploration. The first attempt was made in the early 1980s by Tibblin et al. (5) who proposed a unilateral neck exploration (UNE) based on parathyroid adenoma removal and biopsy of the ipsilateral parathyroid gland to discover possible hyperplasia. In the 1990s UNE evolved towards even more limited surgical approaches: the endoscopic (6) and the radio-guided (7) minimally invasive parathyroidectomy. Two main factors strongly facilitated the development of minimally invasive surgery of solitary parathyroid adenomas. First, the significant improvement achieved in scintigraphic examination after the introduction of MIBI into clinical practice in the late 1980s thanks to Coakley (8). Secondly, the availability of assays for quick parathyroid hormone (PTH) measurement in the operating theatre: it has been demonstrated that a >50% decrease of quick PTH levels after the removal of all hyperfunctioning parathyroid tissue is a strong predictor of complete disease remission (9). Moreover, the worldwide diffusion of probes as intraoperative devices during radio-guided surgery, especially sentinel node biopsy of melanoma and breast cancer patients, further encouraged the development of minimally invasive radio-guided surgery (MIRS) in HPT patients with a solitary parathyroid adenoma.

In the present study, following some preliminary papers from our center (10–13), we report our experience on probe-guided parathyroidectomy obtained in a large series of 214 consecutive primary HPT patients. The study is focused on optimization of the radio-guided technique and on definition of clinical indications for MIRS.

**Patients and methods**

From September 1999 to July 2002, 214 consecutive patients affected by primary HPT were enrolled in the study. Biochemical diagnosis of primary HPT was obtained in all patients. There were 128 females and 86 males, mean age 53.5 years (range 27–81 years). The reasons that led the physician to investigate calcium/phosphate metabolism were as follows: bone pain suggesting osteoporosis in 78% of cases, renal stones in 16%, fatigue and neuro-muscular symptoms in 14%, hypertension in 7%, gastrointestinal symptoms in 4% (two or more of the above symptoms were contemporaneously present in one-third of patients); 12% of patients were asymptomatic and hypercalcemia was incidentally discovered during a routine blood sample analysis. Twenty-seven patients had previously undergone neck surgery for a thyroid nodular goiter or primary HPT in another surgical center.

The preoperative localizing imaging work-up consisted of a double-tracer 99mTc-pertechnetate/MIBI subtraction scan combined with high-resolution neck ultrasound (14). In cases of congruent scan/ultrasound results (both positive or negative) imaging was terminated, while in some cases of discrepancy (scan-positive and ultrasound-negative) for the presence of an enlarged parathyroid gland in the neck or with planar scintigraphy showing an ectopic parathyroid gland, the imaging protocol was completed by tomographic (single photon emission computed tomography (SPECT)) acquisition (n = 36 patients) in order to better define the depth of the parathyroid enlargement. SPECT was performed immediately after planar scintigraphy and ultrasound, thus commencing acquisition 50–60 min after MIBI injection. In this way the same MIBI dose was used for both planar scintigraphy and SPECT.

Patients were selected for MIRS on the basis of the following criteria: (i) scan evidence of a solitary parathyroid adenoma, (ii) a clear MIBI uptake in the parathyroid adenoma, (iii) absence of concomitant MIBI-avid thyroid nodules, (iv) no history of familial HPT or multiple endocrine neoplasia (MEN), and (v) no history of neck irradiation. One hundred and forty-seven patients met these inclusion criteria (68.7% of all cases).

Sixty-seven patients were excluded from MIRS due to: (i) evidence of concomitant MIBI-avid thyroid nodules in 45 patients (21.0% of all cases), (ii) scan/ultrasound findings suggesting a multi-gland parathyroid disease in 13 patients (6.1% of all cases), and (iii) negative scan examination in nine patients (4.2% of all cases; two of whom had a cystic parathyroid adenoma and three of whom had a concomitant large multinodular goiter). In this group of 67 patients the probe was utilized during a traditional BNE.

**Preoperative imaging procedures**

Planar scintigraphy was performed using a technique developed in our center (14) and consisted of the following steps: acquisition – (i) 150 MBq 99mTc-pertechnetate were injected i.v., (ii) 20 min later, 400 mg potassium perchlorate were orally administered, (iii) immediately after potassium perchlorate administration, the patient’s neck was immobilized under the gamma camera and a 5 min thyroid scan was acquired, (iv) 550 MBq MIBI were injected i.v., followed by 30 ml saline with the aim of avoiding radiotracer stagnation, (v) a dynamic acquisition of seven 5 min MIBI scans was obtained; and processing – (vi) background activity was subtracted from 99mTc-pertechnetate and MIBI scans, (vii) normalization of MIBI scans to the maximum pixel count activity of the 99mTc-pertechnetate scan was performed, (viii) the 99mTc-pertechnetate scan was subtracted from the MIBI scan (an interactive software program capable of subtracting incremental fractions of the 99mTc-pertechnetate activity was utilized).
Potassium perchlorate was given with the purpose of speeding up 99mTc-pertechnetate wash-out from the normal thyroid gland, thus obtaining high-quality MIBI scans to highlight also parathyroid adenomas located behind the thyroid gland (Figs 1–3). Scans were interpreted by two nuclear medicine physicians skilled in parathyroid imaging; in cases of discrepancy, the final scintigraphic diagnosis was reached by consensus. In patients with a 99mTc-pertechnetate and ultrasound ‘normal’ thyroid gland, a single focus of MIBI uptake in the MIBI scans and subtraction scans was defined as solitary parathyroid adenoma, while patients with at least two foci of MIBI uptake were considered as being affected by multi-gland disease. In patients with concomitant nodular goiter, correlative ultrasound imaging was used to distinguish parathyroid enlargements from MIBI-avid thyroid nodules.

Planar scintigraphy was acquired by a large-field-of-view gamma camera (Orbiter 7500; Siemens, Hoffman Estates, IL, USA) equipped with a parallel-hole, low-energy, high-resolution collimator. Images were stored in a 128 × 128 matrix and processed using a dedicated computer (ICON-P; Siemens).

SPECT acquisition was performed by a dual-head gamma camera (Axis; Picker International, Cleveland, OH, USA) equipped with a parallel-hole low-energy ultra-high-resolution collimator. The following parameters were adopted: elliptical orbit, 120 steps, 30 s per step, 64 × 64 matrix. Images were reconstructed using a low-pass filter, cut-off 0.2, order 5.0–6.0, and processed using a dedicated computer (Odyssey 830 Digital, Maynard, MA, USA). 3-D analysis was also obtained.

In the subgroup of 36 patients in whom a SPECT acquisition was obtained following a positive planar scintigraphy, SPECT suggested a deep location of the parathyroid enlargement in 14 patients and in these cases a parathyroid adenoma was found at surgery in the para-tracheal/para-esophageal space (ten in the neck, four in the upper mediastinum).

A high-resolution 10 MHz transducer was utilized for ultrasound examination (Technos, Esaote, Italy). Longitudinal and transverse neck scans were obtained from the angle of the mandible to the sternal notch. The enlarged parathyroid gland was identified on grayscale imaging by the characteristic appearance of a hypo-echoic nodule distinct from the thyroid gland.

Intraoperative probe-guided procedure

The MIRS procedure we are currently using was developed in our center in 1999 and the first patients were operated on in September 1999. Before that time, our surgeons performed a scan-direct UNE as previously described (11). The MIRS protocol consisted of the following steps: (i) blood samples were drawn from a peripheral vein during anesthesia induction, just before skin incision and 10 min after removal of the parathyroid adenoma to measure quick PTH levels, (ii) 37 MBq MIBI were injected i.v. in the operating theatre a few minutes before the start of surgery – the injection was followed by a flush of 30 ml saline to avoid radiotracer stagnation, (iii) prior to the surgical incision, the patient’s neck was scanned with an 11 mm gamma probe to individualize the maximum count activity area corresponding to the parathyroid adenoma, (iv) a middle neck access at the level of the sternal notch was utilized, (v) the probe was inserted through a 2–2.5 cm skin incision after strap muscle retraction, (vi) the probe guided the surgeon to the maximum count activity area corresponding to the parathyroid adenoma (in some patients with a parathyroid adenoma located deep in the neck, a ligature of the middle thyroid vein and sometimes of the inferior thyroid artery was necessary to better visualize the adenoma), (vii) radioactivity was measured on the parathyroid adenoma, thyroid gland and background, (viii) the parathyroid adenoma was removed using microsurgery instruments, (ix) radioactivity was

![Figure 1](99mTc-pertechnetate scan (left image) shows a normal thyroid gland. MIBI scan (middle image) and subtraction image (right image) show a right superior solitary parathyroid adenoma located behind the thyroid lobe. The patient was treated by MIRS (adenoma weight = 840 mg).)
checked on the ‘ex vivo’ parathyroid adenoma as well as on the empty parathyroid bed. (x) tissue ratios were calculated.

In patients with concomitant MIBI-avid nodular goiter, the radioactivity was intraoperatively measured also on the thyroid nodules.

A hand-held commercially available gamma collimated probe (Scintiprobe 100; Pol.hi.tech., Italy) was used. Technical characteristics are as follows: linear probe with an external diameter of 11 mm, mounting a shielded NaI detector; energy range 30–385 keV; gamma detecting efficiency of 99% for 99mTc peak energy (140 keV); sensitivity threshold of 10 nCi and spatial resolution of 5 mm at a 2 mm distance.

Intraoperative quick PTH was measured by chemoluminescence assay (Liason, Byk Gulden, Italy – normal value 10–54 pg/ml). A fall of 50% or more in PTH levels 10 min after the parathyroid adenoma removal in comparison with the baseline pre-excision value was considered as indicative of successful parathyroidectomy. Additional blood samples for quick PTH measurement were obtained in patients with multi-gland disease 10 min after the removal of all hyperfunctioning parathyroid tissue.

All patients were operated on by the same surgical team. Time from preoperative scan/ultrasound imaging to surgery ranged from 1 to 21 days; in the majority of cases this time interval was >3 days. In only four cases was surgery performed the day after scintigraphy; in these patients no significant radioactivity was detected in the neck by the probe before the injection of the 37 MBq MIBI dose required for MIRS.

Post-surgical follow-up ranged from 3 to 34 months, mean±S.D. 7.8±5.6 months.

After surgery, patient received clinical and laboratory surveys 1 month later and subsequently every 2–3 months.

Data are expressed as means±1 S.D. Mean values were compared using Student’s t-test. P values <0.05 were considered significant.
Results

Patients selected for MIRS (n = 147)

One hundred and forty-four patients from this group (97.9% of cases) were successfully treated by MIRS. The probe was particularly helpful in guiding the surgeon to detect 12 ectopic parathyroid adenomas in the upper mediastinum and one at the carotid bifurcation, and ten parathyroid adenomas located deep in the neck in the para-esophageal/para-tracheal space. MIRS required a mean operating time of 35 min (range 15 – 58) and a mean hospital stay of 1.2 days (range 1 – 2). Local anesthesia was performed in 14 patients. No case of laryngeal nerve palsy or permanent hypoparathyroidism was recorded. Transient hypoparathyroidism was observed in 9% of cases. From a cosmetic point of view, a small 2 cm skin incision was usually sufficient to perform a MIRS (against the large > 4 cm skin incision necessary to perform a traditional BNE). In all patients but one, quick PTH levels decreased > 50% in comparison with the pre-excision value 10 min after theadenoma removal. Conversion to BNE was required in only three patients (2.1% of cases). In one of these three patients quick PTH levels remained elevated after removal of the preoperatively visualized parathyroid adenoma, and another parathyroid adenoma was found at surgery in the contralateral side of the neck (final diagnosis was of double adenoma). In the other two patients a parathyroid carcinoma was diagnosed during intervention and a subtotal thyroidectomy was added to the parathyroidectomy: no loco-regional metastatic spread was found.

Of note, the probe allowed us to perform a MIRS also in 18 out of the 27 patients who had received previous thyroid/parathyroid surgery in another surgical center. All patients of this group were eucalcemic and had PTH levels within the normal range during the post-surgical follow-up (range 3 – 34 months, mean 8.0 ± 5.7 months).

Patients selected for BNE (n = 67)

The probe was of little help in this patient group. In particular, in the subgroup of patients with multi-gland disease the probe helped the surgeon in detecting one ectopic parathyroid gland located in the thymus in one patient; in the subgroup of 45 patients with concomitant nodular goiter the probe was useful to detect an ectopic parathyroid adenoma located at the carotid bifurcation in one patient, and a parathyroid adenoma located deep in the para-esophageal/para-tracheal space in four other patients. However, it has to be pointed out that in some other patients with a parathyroid adenoma located near to the nodular goiter it was difficult to intraoperatively distinguish the radioactivity of the parathyroid adenoma form that of the MIBI-avid thyroid nodules, especially in cases in whom the MIBI uptake was higher in the thyroid nodules than in the parathyroid adenoma. Lastly, in our experience the probe was not useful in the subgroup of patients with a negative preoperative MIBI scan. No case of laryngeal nerve palsy was recorded in patients treated by BNE, while two cases of recurrent HPT (hyperplasia in both cases, in one case MEN-related) were observed during the subsequent follow-up. The rate of transitory hypocalcemia was higher than in patients treated by MIRS (26%) and, as expected, also the time of intervention was longer (mean 58 min, range 32 – 90) as well as the hospital stay (mean 2.5 days, range 2 – 3).

Quick PTH levels reduced > 50% in all cases after removal of all detected enlarged parathyroid glands. All patients but two were eucalcemic during the post-surgical follow-up (range 3 – 29 months, mean 7.5 ± 6.1). Of note, during operation, quick PTH showed a decrease > 50% also in the two patients who presented recurrent HPT during follow-up.

The size of removed solitary parathyroid adenomas did not significantly differ between patients treated by MIRS and those treated by BNE (mean weight 915 ± 293 vs 976 ± 343 mg respectively). Parathyroid glands were smaller in patients with multi-gland disease (564 ± 276 mg; P < 0.05).

We did not perform a randomized study to compare MIRS with traditional BNE in patients with a solitary parathyroid adenoma. However, considering the historical data of our surgical center, both the operating time and the hospital stay were approximately doubled with BNE rather than MIRS.

The radiation exposure dose (calculated in patients who had scintigraphy at least 2 days before surgery) was 1.20 μSv/h to the surgeon’s body and 5.00 μSv/h to the surgeon’s hands, which is significantly lower than the annual radiation dose limits recommended for the general population by the International Commission on Radiological Protection, i.e. 1000 μSv for the body and 50 000 μSv for the hands.

Discussion

In a recent survey from the members of the International Association of Endocrine Surgeons (160 surveys) (15) it emerged that in the year 2000 59% of surgeons worldwide were using some type of minimally invasive parathyroidectomy: the video-assisted technique was used by 22% of surgeons, the true endoscopic technique by 12% and the probe-guided technique by 14%; moreover, quick PTH was measured by 68% of surgeons.

In contrast to BNE, when considering a MIRS, strict inclusion criteria have to be followed, in particular a high probability of a solitary adenoma established on the basis of a MIBI scan and a significant MIBI uptake in the adenoma, while patients with concomitant
MIBI-avid thyroid nodules, history of familial HPT or MEN or previous neck irradiation should be excluded from MIRS (10–13, 16). As a consequence, only a proportion of primary HPT patients, accounting for about 60–70% of all cases, can be selected for MIRS (10–13, 16). Moreover, while preoperative imaging could be considered unnecessary when performing a BNE, a MIBI scan becomes mandatory in the view of a MIRS. Various types of preoperative scintigraphic techniques are currently used, the most sensitive being the single-tracer dual-phase SPECT and the double-tracer subtraction technique (17–22). The double-tracer technique offers the advantage of being more specific than the dual-phase technique because it allows diagnosis of thyroid nodular disease concomitant with parathyroid tumors. For this reason the double-tracer scan is usually preferred in geographic areas with a high prevalence of nodular goiter (21, 23). We utilize a double-tracer subtraction scintigraphy using 99mTc-pertechnetate as a thyroid agent, which is significantly cheaper than 123I (14). Moreover, a correlative ultrasound imaging is useful to differentiate thyroid from parathyroid enlargements (21, 23).

Regarding the intraoperative probe techniques, three principal protocols have been described. The first one was developed by Norman in 1997 (7) consisting of a single-day imaging and surgery approach: the patient is injected with a 740 MBq dose of MIBI, scintigraphy is obtained by dual-phase technique, and within 3 h from MIBI injection the patient is operated on. Norman’s protocol is very attractive, especially from a cost-effectiveness point of view because imaging and surgery are obtained on a single-day basis and, thus, the same MIBI dose is utilized for both imaging and MIRS. A different-day imaging and surgery protocol was proposed by Flynn et al. (24): a MIBI scan is obtained by a dual-phase technique and, usually the day after, the patient is re-injected with an additional high (740 MBq) MIBI dose 60–90 min before surgery. The protocol we developed consists of a different-day imaging and surgery protocol: the scintigraphic examination is obtained by a 99mTc-pertechnetate/MIBI subtraction technique and some days later, for the purpose of probe-guided surgery only, the patient is re-injected with a low (37 MBq) MIBI dose in the operating theatre a few minutes before the start of surgery. The ‘low MIBI dose protocol’ we propose provides two advantages. First, the radiation exposure dose to both the patient and the surgeon is minimized. Secondly, potential false-negative results due to parathyroid adenomas characterized by a relatively fast MIBI wash-out can be avoided. Furthermore, we prefer using a different-day protocol with the aim of better planning the operating daily program: extension of surgery, time per intervention, number of patients scheduled per day. Thus, even if the single-day protocol of Norman (7) can be considered as the ideal protocol when planning a MIRS, a different-day protocol is probably preferable in geographic areas with a high prevalence of nodular goiter, in order to better select the patients. Again, while in a single-day protocol the injection of a high 740 MBq MIBI dose is required to obtain a scan before surgery, in a different-day protocol a low 37 MBq MIBI dose appears to be adequate to perform a probe-guided surgery (25); thus when using a different-day protocol it does not appear justifiable to re-inject the patient with an additional high 740 MBq MIBI dose.

The main advantages derived by using the gamma probe in our experience were: (i) a rapid intraoperative detection of parathyroid adenomas, especially those located in an ectopic site or deep in the neck, (ii) the evaluation of surgical completeness by checking radioactivity in the empty parathyroid bed after adenoma removal, and (iii) the evaluation of surgical effectiveness by measuring radioactivity on the ex vivo parathyroid adenoma. A quantitative analysis of the ex vivo radioactivity measured on the removed parathyroid tissue has been proposed by Murphy & Norman (26). Every surgical specimen measuring more than 20% of background activity was defined as a solitary parathyroid adenoma; applying this parameter, named the ‘20% rule’, the authors found a 100% accuracy in distinguishing solitary adenomas from multi-gland disease in a very large series of 345 HPT patients. Based on these data, the authors concluded that the performing of frozen section analysis and measurement of quick PTH were unnecessary. These exciting results were not confirmed in other studies (16). Moreover, in our experience the ex vivo radioactivity counting was higher than 40% in all cases of solitary parathyroid adenoma but also in at least one (dominant) of the enlarged parathyroid glands removed in patients with multi-gland disease. One possible explanation for this discrepancy might be the different timing of MIBI injection and probe measurements: 2–3 h in Norman’s protocol (7, 26) but 20–30 min in our protocol. In this regard, as first demonstrated by O’Doherty et al. in 1992 (18), MIBI reaches the maximum concentration in the parathyroid adenoma within a few minutes from injection; then a slow wash-out is usually observed. Thus, it can be concluded that the ‘20% rule’ is strictly dependent on the type of protocol utilized and can probably only be applied to the Murphy & Norman protocol (26). Furthermore, in our experience quick PTH was very helpful in some patients with multi-gland disease in whom one enlarged parathyroid gland showed a high probe count rate (dominant) while the other enlarged glands were characterized by a relatively low probe count rate; this finding could lead the surgeon to underestimate multi-gland disease while the persistence of elevated quick PTH levels induces the surgeon to continue exploration. Lastly, in a recent study of Jaskowiak et al. (27), performed on 54 primary HPT patients treated by probe-guided surgery, the...
‘20% rule’ was efficacious in identifying all solitary parathyroid adenomas (100% sensitivity). Unfortunately, the authors did not obtain data about patients with multi-gland disease. However, interestingly they observed that the application of merely the ‘20% rule’ gave false-positive results in the majority of patients with concomitant thyroid nodules (six of seven cases, 85.7%) thus heavily affecting specificity. Of note, the authors utilized a dual-phase MIBI technique for the preoperative scan that is recognized as being inaccurate in distinguishing parathyroid adenomas from MIBI-avid thyroid nodules; in these cases a double-tracer scintigraphy would be preferred (21, 23) and probe-guided surgery should be avoided as confirmed by the results of our study. For the above-cited reasons, at the moment, when performing a MIRS, it appears reasonable to recommend a quick PTH measurement with the aim of further evaluating the completeness of all hyperfunctioning parathyroid tissue removal.

It has to be pointed out that in our experience MIRS was successfully performed also in a high percentage of patients (18 of 27, 66.6%) who had previous thyroid/parathyroid surgery, thus minimizing the risks of possible intraoperative complications. Similar favorable results have been recently reported by Norman & Denham (28) in re-operative HPT patients. Of note, in contrast to probe-guided surgery, endoscopic surgery has not been proposed for re-operation (29).

A technical aspect to be discussed concerns the utilization of collimated or non-collimated probes. Perrier et al. (16) reported favorable results using a non-collimated probe. However, collimated probes offer the advantage of avoiding or minimizing the interfering radioactivity from the surrounding tissues, especially from the thyroid gland (25).

From a surgical point of view, we prefer using a middle neck access mainly because conversion to a BNE can be easily performed when necessary. Using a middle access, MIRS was successfully performed in 98% of patients in our series. However, it is worth noting that other authors reported similarly good results using a lateral neck access (7, 24, 26, 30). Probably this issue strictly depends on the surgeon’s own experience and convenience.

In our study the probe was not helpful in primary HPT patients with a negative preoperative MIBI scan. This is in contrast to the experiences of Bonjer et al. (31) and Jaskowiak et al. (27) who claimed that a major role of the gamma probe was the intraoperative detection of unknown (scan-negative) hyperfunctioning parathyroid glands during BNE. This discrepancy might be explained, at least in part, by considering the relatively lower sensitivity of the preoperative scintigraphy used by Bonjer et al. (31) and Jaskowiak et al. (27) (dual-phase technique) in comparison with our scintigraphic procedure (double-tracer technique); sensitivity for detection of parathyroid adenomas was 60–74% vs 95% respectively.

It appears surprising that such different and opposite opinions have been reported in the literature on the role of the gamma probe during parathyroidectomy, ranging from enthusiastic considerations (7, 26, 28), to less favorable results (16, 27), to a judgment of uselessness (32). Some explanations can be made. Interestingly, Jaskowiak et al. (27), proposed a four-point scale to define the probe-guided surgery in a group of 54 patients treated by BNE: the probe was judged crucial in only two patients (4%), helpful in 12 (22%), merely confirmatory in 32 (59%) and not helpful in eight (15%). In contrast, in our experience as well as in that of Norman et al. (7, 26, 28) the probe was helpful in the majority of scan-positive patients and very helpful or even crucial in patients with adenomas located in ectopic sites or deep in the para-tracheal/para-esophageal space. This difference in judging probe utility could be related, at least in part, to the different surgical approaches utilized: a BNE in Jaskowiak’s study (27) while a MIRS in our own study and in Norman’s studies (7, 26, 28). From this view, it appears reasonable to think that it can be relatively easy for an experienced surgeon to detect a parathyroid adenoma located in an orthotopic site during a BNE simply using the ‘eyes’; conversely, it can be difficult, even for an experienced surgeon, to detect a parathyroid adenoma through a 2 cm skin incision without the help of a ‘gamma probe’: thus, following Jaskowiak’s criteria (27) what is judged as ‘merely confirmatory’ during a BNE could be ‘helpful’ during a MIRS and what is judged as ‘helpful’ during a BNE could be ‘crucial’ during a MIRS.

Debate exists about the cost-effectiveness analysis of probe-guided surgery (7, 10–13, 16, 24–30). It depends upon various factors: (i) when a MIRS is planned, a preoperative MIBI scan is necessary, (ii) the single-day protocol takes advantage of using a single MIBI dose for preoperative imaging and probe-guided surgery, (iii) in the case of a different-day imaging and surgery protocol two doses of MIBI are required, (iv) the purchase of the gamma probe and connected electronic devices, and (v) the ability or not to perform also frozen section analysis and quick PTH measurement. All of these items have a cost that can, however, vary from country to country and depends also upon the local care rules and objectives. In our surgical center the gamma probe was already available when we started performing MIRS, since it was used for sentinel node biopsy of melanoma and breast cancer patients. Moreover, in our nuclear medicine unit MIBI is utilized on a daily basis for various types of scintigraphic examinations such as myocardial, breast and thyroid cancer scans (33) and consequently the cost of a MIBI dose as low as 37 MBq to perform a MIRS is essentially negligible. Regarding quick PTH, its measurement has been used in our center for many years and is currently utilized by our surgeons independent of the type of parathyroid surgery they plan.
i.e. during both BNE and MIRS. Most importantly, some of the principal objectives of our hospital administration are to reduce operating time, increase the daily number of patients scheduled for intervention, and reduce the hospital stay: in our experience the utilization of the gamma probe facilitated the reaching of these objectives in primary HPT patients.

It can be concluded that: (i) in geographic areas with high prevalence of nodular goiter, the combination of MIBI scan, performed by double-tracer technique, and neck high-resolution ultrasound is an accurate protocol in selecting primary HPT patients as candidates for a probe-guided minimally invasive parathyroidectomy, also in patients who need re-operation, (ii) when using a different-day imaging and surgery protocol a MIBI dose as low as 37 MBq appears to be adequate for the purpose of MIRS, (iii) with the possible exception of parathyroid adenomas located deep in the neck or in an ectopic site, probe-guided surgery does not appear recommendable in patients with concomitant nodular goiter, and (iv) at the moment, it appears recommendable to measure quick PTH levels during MIRS with the aim of further evaluating completeness of all hyperfunctioning parathyroid tissue removal.

Acknowledgements

This paper was presented by invitation at the Royal College of Surgeons Meeting. Parathyroid Localisation – Utility of Diagnostic Imaging, held in London on 22 November 2002.

References

33 Rubello D, Mazzarotto R & Casara D. The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma. European Journal of Nuclear Medicine 2000 27 431–440.